CNBC October 15, 2024
Key Points
– U.S. pharmaceutical giant Eli Lilly is exploring whether obesity drugs could be used to curb joblessness after signing a major investment deal with the U.K.
– The U.S. pharmaceutical company and creator of blockbuster obesity injection Zepbound announced Monday that it would commit £279 million ($364 million) to help tackle Britain’s significant health challenges.
– The Eli Lilly deal includes a “real-world” study into how its weight-loss drugs impact “participants’ employment status and sick days,” among other factors.
LONDON — U.S. pharmaceutical giant Eli Lilly is exploring whether obesity drugs could be used to curb joblessness after signing a major investment deal with the U.K.
The weight-loss treatment firm and creator of Zepbound announced Monday that it...
Today's Sponsors
Today's Sponsor